Comparative Pharmacology
Head-to-head clinical analysis: ACETOHEXAMIDE versus AMARYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETOHEXAMIDE versus AMARYL.
ACETOHEXAMIDE vs AMARYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels (K_ATP), causing membrane depolarization, calcium influx, and exocytosis of insulin-containing granules. Also may increase peripheral insulin sensitivity.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, causing channel closure and calcium influx.
Initial: 250 mg orally once daily; maintenance: 250-1500 mg orally once daily or in divided doses twice daily.
Initial dose 1-2 mg orally once daily, titrated to target glucose. Maximum dose 8 mg daily.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (parent drug); ~5-6 hours (active metabolite hydroxyhexamide); clinical context: prolonged in renal impairment due to accumulation of active metabolite
Terminal elimination half-life is 5-7 hours; clinically, dosing is once daily due to sustained glucose-lowering effect beyond half-life.
Renal: 85-90% (60-70% as unchanged drug, remainder as hydroxylated metabolite); biliary/fecal: <10%
Approximately 60% excreted renally as metabolites (mainly M1 and M2) and 40% in feces; <1% excreted unchanged.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic